PPARG and steatosis: In terms of implemented therapeutic interventions, vitamin E and the PPARγ ligand pioglitazone have beneficial effects on steatosis and inflammation, but they do not improve fibrosis, the strongest indicator of mortality in NAFLD/NASH.